医学临床研究
  2025年4月5日 星期六           首 页    |    期刊简介    |    编委会    |    投稿指南    |    期刊订阅    |    广告合作    |    留言板    |    联系我们    |    English
医学临床研究  2021, Vol. 38 Issue (7): 1075-1078    DOI: 10.3969/j.issn.1671-7171.2021.07.033
  论著 本期目录 | 过刊浏览 | 高级检索 |
抗血管生成药物联合紫杉醇和顺铂在非小细胞肺癌中应用价值分析
谢琳, 怀宝华
山东省立第三医院肿瘤中心,山东 济南 250031
Application Value of Anti-angiogenesis Drugs Combined with Paclitaxel and Cisplatin in Non-small Cell Lung Cancer
XIE Lin, HUAI Bao-hua
Shandong Provincial Third Hospital,Cancer Center,Jinan Shandong 250031
全文: PDF (1177 KB)   HTML (1 KB) 
输出: BibTeX | EndNote (RIS)      
摘要 【目的】探讨抗血管生成药物联合紫杉醇和顺铂在非小细胞肺癌(NSCLC)中的应用价值。【方法】选取本院收治的NSCLC患者80例,根据治疗方案不同分为对照组(n=40,紫杉醇和顺铂化疗)和观察组(n=40,贝伐珠单抗联合紫杉醇和顺铂化疗),对比两组患者的临床有效率、肿瘤标志物及免疫学指标变化、生活质量和不良反应发生情况。【结果】观察组总有效率为57.5%(23/40),高于对照组的25.00%(10/40),且两组相比较差异有显著性(P<0.05);两组患者治疗后癌胚抗原、血管内皮生长因子(VEGF)、碱性纤维细胞生长因子(bFGF)均较治疗前有所改善(P<0.05),且观察组优于对照组(P<0.05);治疗后观察组免疫学指标CD3+、CD4+、CD8+、CD4+/CD8+水平较治疗前上升(P<0.05);对照组CD3+、CD4+、CD8+较治疗前下降(P<0.05),观察组各项指标高于对照组(P<0.05);观察组生活质量评分为(46.81±7.58)分,高于对照组的(38.17±7.29)分(P<0.05);两组不良反应发生率相比较差异无显著性(P>0.05)。【结论】抗血管生成药物联合紫杉醇和顺铂治疗NSCLC临床疗效更高、不良反应较少,可有效改善免疫系统受损、促进肿瘤标志物恢复正常、提高患者生活质量。
服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
谢琳
怀宝华
关键词 非小细胞肺/药物疗法抗肿瘤药/治疗应用紫杉烷类/治疗应用卡铂/治疗应用    
Abstract:【Objective】 To investigate the application value of anti angiogenesis drugs combined with paclitaxel and cisplatin in non-small cell lung cancer(NSCLC).【Methods】A total of 80 patients with NSCLC in our hospital were selected and divided into control group(n=40, paclitaxel and cisplatin chemotherapy) and observation group(n=40, bevacizumab combined with paclitaxel and cisplatin chemotherapy) according to different treatment schemes. The clinical effective rate, changes of tumor markers and immune indexes, quality of life and adverse reactions of the two groups were compared. 【Results】The total effective rate of the observation group was 57.5%(23/40), which was higher than 25.00%(10/40) of the control group, and there was significant difference between the two groups(P<0.05); Carcinoembryonic antigen, vascular endothelial growth factor(VEGF) and basic fibroblast growth factor(bFGF) of the two groups were improved after treatment(P<0.05), and the observation group was better than the control group(P<0.05); After treatment, the levels of CD3+ CD4+ CD8+ CD4+/CD8+ in the observation group were higher than those before treatment(P<0.05); The levels of CD3+ CD4+ CD8+ in the control group were lower than those before treatment(P<0.05), and the indexes in the observation group were higher than those in the control group(P<0.05); The quality of life score of the observation group was(46. 81±7. 58) was higher than(38. 17 ±7. 29)(P<0.05); There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05). 【Conclusion】 Anti angiogenic drugs combined with paclitaxel and cisplatin in the treatment of NSCLC has higher clinical efficacy and fewer adverse reactions, which can effectively improve the immune system damage, promote the recovery of tumor markers and improve the quality of life of patients.
Key wordsCarcinoma, Non-Small-Cell Lung/DT    Antineoplastic Agents/TU    Taxoids/TU    Carboplatin/TU
收稿日期: 2021-03-19     
中图分类号:  R734.2  
引用本文:   
谢琳, 怀宝华. 抗血管生成药物联合紫杉醇和顺铂在非小细胞肺癌中应用价值分析[J]. 医学临床研究, 2021, 38(7): 1075-1078.
XIE Lin, HUAI Bao-hua. Application Value of Anti-angiogenesis Drugs Combined with Paclitaxel and Cisplatin in Non-small Cell Lung Cancer. JOURNAL OF CLINICAL RESEARCH, 2021, 38(7): 1075-1078.
链接本文:  
http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2021.07.033     或     http://journal07.magtech.org.cn/yxlcyj/CN/Y2021/V38/I7/1075
版权所有 © 2013 医学临床研究杂志社  湘ICP备13012052号-1
办公地址:湖南省长沙市芙蓉区新军路43号煤炭大院主办公楼6楼621、623、632、636室 邮编:410011 电话(传真):0731-84824007 E-mail:jcr_cs.hn@vip.163.com
技术支持:北京玛格泰克科技发展有限公司 技术支持:support@magtech.com.cn